The pharmaceutical industry is heading into 2027 with growth becoming increasingly concentrated in therapeutic areas where innovation, unmet need and large patient populations overlap.
IQVIA forecasts global medicine spending to reach about $2.6 trillion by 2030, with oncology, immunology, diabetes and obesity expected to remain the biggest contributors to growth.
The opportunity is not limited to the largest markets. New modalities, expanding indications, aging populations and stronger clinical pipelines are creating attractive growth pockets across several therapeutic areas.
| Therapeutic Area | Key 2025/2026 Statistic | What It Signals for 2027 |
|---|---|---|
| Oncology | $288B global spending in 2025 | Largest pharmaceutical innovation and spending pool |
| Obesity | $66B global spending in 2025 | Rapid expansion of GLP-1 and next-generation incretin therapies |
| Immunology | One of the largest contributors to medicine-spending growth through 2030 | Continued biologic and targeted-therapy demand |
| Diabetes | Among the major global medicine-spending growth drivers | Increasing convergence with obesity and cardiometabolic care |
| Neurology | 9% of biopharma M&A value in H1 2026 | Strong investor interest in CNS innovation |
| Rare Diseases | 23 of 46 FDA novel drugs in 2025 had orphan designation (50%) | Precision medicine remains a major R&D opportunity |
| Cardiovascular | PCSK9 and other lipid therapies driving innovation | Shift toward advanced prevention and cardiometabolic treatment |
| Respiratory | Novel biologics expanding severe asthma treatment | Greater adoption of biomarker-driven therapies |
| Women’s Health | 9% of biopharma M&A value in H1 2026 | Rising strategic and investment attention |
| Ophthalmology | Multiple novel ophthalmic therapies entering the market | Aging population and advanced delivery technologies support growth |
1. Oncology – $288B market in 2025
Oncology remains the industry’s biggest therapeutic area, with global sales reaching approximately $288 billion in 2025. Solid tumors alone generated around $194 billion, led by breast, lung and prostate cancers.
The next phase of growth is increasingly modality-driven, with antibody-drug conjugates, bispecific antibodies, radiopharmaceuticals and targeted immunotherapies reshaping the competitive landscape.
2. Obesity – Nearly $66B in 2025
Obesity has become one of pharma’s fastest-moving markets, reaching nearly $66 billion in global sales in 2025. IQVIA expects the market to approach $92 billion in 2026 as oral therapies broaden access.
The bigger opportunity is the expansion of obesity medicines into diabetes, cardiovascular and kidney-related indications, turning GLP-1 and next-generation incretin therapies into broader cardiometabolic platforms.
3. Immunology – A major long-term growth engine
Immunology continues to rank among the largest contributors to pharmaceutical spending growth through 2030, despite increasing biosimilar pressure in established biologic categories.
The market is moving toward more selective mechanisms, differentiated biologics and therapies that can address multiple immune-mediated diseases.
4. Diabetes – $184B projected by 2028
Diabetes remains one of the industry’s largest chronic-care markets, with IQVIA previously projecting global spending of approximately $184 billion by 2028.
The therapeutic area is also converging with obesity, cardiovascular disease and kidney disease, creating opportunities for combination strategies and next-generation metabolic therapies.
5. Neurology – 9% of 2026 M&A value
Neurology is becoming a major investment destination as Alzheimer’s, Parkinson’s, migraine and other CNS conditions attract increasingly sophisticated drug development.
The signal is also visible in dealmaking: neurology represented 9% of biopharma M&A value in the first half of 2026, according to IQVIA.
6. Rare Diseases – 50% of FDA’s 2025 novel drugs
Rare disease innovation is becoming increasingly important to pharma portfolios. The FDA approved 46 novel drugs in 2025, and exactly 23 received Orphan Drug Designation.
Gene therapies, RNA medicines, precision treatments and therapies for genetically defined populations are expanding the commercial potential of previously underserved diseases.
7. Cardiovascular – A new cardiometabolic cycle
Cardiovascular medicine is entering another innovation cycle, particularly around lipid management, heart failure and genetically validated targets.
IQVIA specifically highlights renewed growth in lipid regulators, supported by newer PCSK9-targeting therapies, while cardiometabolic disease is becoming increasingly connected with obesity and diabetes.
8. Respiratory – Biologic treatment is expanding
Respiratory medicine is moving beyond traditional inhaled therapies as biologics increasingly target specific inflammatory pathways.
The FDA’s 2025 novel approvals included depemokimab for severe eosinophilic asthma, showing how precision immunology continues to expand into respiratory disease.
9. Women’s Health – 9% of 2026 M&A value
Women’s health is becoming a more visible pharmaceutical investment category, spanning reproductive health, menopause, endometriosis and fertility.
The momentum is evident in dealmaking: women’s health accounted for 9% of biopharma M&A value in the first half of 2026, placing it among the five leading therapeutic areas by deal value.
10. Ophthalmology – Precision therapies create new space
Ophthalmology continues to benefit from aging populations and the growing burden of retinal and metabolic eye diseases.
The pipeline is increasingly focused on longer-acting treatments, targeted biologics, gene therapies and novel delivery technologies. The FDA’s 2025 approvals included Tryptyr, a first-in-class treatment for dry eye disease, highlighting continued innovation beyond traditional retinal therapies.
What Pharma Leaders Should Watch
The key takeaway for 2027 is that therapeutic-area growth is no longer determined by market size alone.
Companies need to evaluate pipeline quality, Phase II-to-III progression, modality adoption, M&A activity, patent exposure, competitive density, reimbursement and patient access alongside market forecasts.
This matters because R&D activity is increasingly concentrated around high-value science. IQVIA reported that emerging biopharma companies drove 68% of clinical trial starts, while oncology, immunology, neurology and obesity remained among the major areas of development focus.
For pharma and biotech decision-makers, the opportunity is therefore not simply to identify the fastest-growing therapeutic area. It is to identify where growth, clinical differentiation and competitive whitespace are likely to intersect before the market becomes overcrowded.
About Us
Healthcare WebWire is a part of Towards Healthcare Research & Consulting which is a global healthcare market research and consulting firm dedicated to helping businesses make informed decisions through reliable market intelligence and strategic insights. We serve pharmaceutical, biotechnology, medical device, AI in healthcare, cell and gene therapy, digital health, and life sciences organizations with in-depth market research, custom consulting, competitive analysis, and growth forecasts. Our team combines industry expertise with rigorous research to deliver clear, actionable insights that support market expansion, product strategy, investment decisions, and long-term business growth. From emerging innovations to established healthcare markets, we help organizations understand where the industry is today and where it’s headed tomorrow.
For more enquiry you can connect with us at: [email protected]
You can place an order or ask any questions, please feel free to contact us at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium